STOCK TITAN

[Form 4] ANGIODYNAMICS INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

AngioDynamics (ANGO) reported insider activity by its EVP and CFO. A Form 4 shows a purchase of 890 shares of common stock on 10/13/2025 at a price of $11.16 per share, coded “P” for a purchase.

Following the transaction, the reporting person beneficially owns 256,629 shares, held directly. The filing indicates the role as EVP and CFO and confirms the report was filed by one reporting person.

AngioDynamics (ANGO) ha comunicato attività interne da parte del suo EVP e CFO. Un Form 4 mostra l'acquisto di 890 azioni comuni il 13/10/2025 al prezzo di $11,16 per azione, codificato “P” per un acquisto.

Dopo la transazione, la persona che presenta il rapporto detiene in modo beneficiante 256.629 azioni, detenute direttamente. Il modulo indica il ruolo come EVP e CFO e conferma che il rapporto è stato presentato da una persona informante.

AngioDynamics (ANGO) informó actividad de insiders por su vicepresidente ejecutivo de operaciones y su director financiero. Un Formulario 4 muestra la compra de 890 acciones de acciones comunes el 13/10/2025 a un precio de $11,16 por acción, codificado como “P” para una compra.

Después de la transacción, la persona reportante posee de forma beneficiosa 256.629 acciones, manteniéndolas directamente. El documento indica el cargo como EVP y CFO y confirma que el informe fue presentado por una persona informante.

AngioDynamics (ANGO) 은 EVP 및 CFO의 내부자 활동을 보고했습니다. Form 4는 890주의 보통주를 2025-10-13$11.16의 가격으로 매입했음을 “P”로 코딩해 보여줍니다.

거래 후 보고자 은 256,629주의 주식을 직접 보유하고 있습니다. 신고서에는 역할이 EVP 및 CFO로 표시되며 한 명의 보고자가 서류를 제출했다고 확인합니다.

AngioDynamics (ANGO) a signalé une activité d'initié par son EVP et CFO. Un Formulaire 4 montre l'achat de 890 actions de actions ordinaires le 13/10/2025 à un prix de $11,16 par action, codé « P » pour un achat.

Suite à la transaction, la personne déclarant détient favorablement 256 629 actions, détenues directement. Le dépôt indique le rôle comme EVP et CFO et confirme que le rapport a été déposé par une seule personne déclarant.

AngioDynamics (ANGO) meldete Insider-Tätigkeit seines EVP und CFO. Ein Formular 4 zeigt den Kauf von 890 Aktien der Stammaktien am 13.10.2025 zu einem Preis von $11,16 pro Aktie, codiert als „P“ für einen Kauf.

Nach der Transaktion besitzt die meldende Person 256.629 Aktien, direkt gehalten. Die Einreichung gibt die Rolle als EVP und CFO an und bestätigt, dass der Bericht von einer meldenden Person eingereicht wurde.

AngioDynamics (ANGO) أعلن عن نشاط داخلي من قبل نائب الرئيس التنفيذي للعمليات والمدير المالي. يظهر نموذج 4 شراء 890 سهماً من الأسهم العادية في 13/10/2025 بسعر $11.16 للسهم، مُرمَّز بـ “P” لشراء.

بعد الصفقة، يمتلك الشخص المبلغ عنه بشكل مستفيد 256٬629 سهماً، وهو مملوك مباشرةً. يبيّن ملف الإبلاغ الدور كـ EVP و CFO ويؤكد أن التقرير قد قدمته شخص واحد مُبلغ.

AngioDynamics (ANGO) 报告其执行副总裁兼首席财务官的内部交易。Form 4 显示在 2025/10/13 以每股 $11.16 的价格购买了 890 股普通股,标记为“P”表示购买。

交易完成后,申报人实际持有 256,629 股,直接持有。档案显示该角色为 EVP 和 CFO,并确认报告由一位申报人提交。

Positive
  • None.
Negative
  • None.

AngioDynamics (ANGO) ha comunicato attività interne da parte del suo EVP e CFO. Un Form 4 mostra l'acquisto di 890 azioni comuni il 13/10/2025 al prezzo di $11,16 per azione, codificato “P” per un acquisto.

Dopo la transazione, la persona che presenta il rapporto detiene in modo beneficiante 256.629 azioni, detenute direttamente. Il modulo indica il ruolo come EVP e CFO e conferma che il rapporto è stato presentato da una persona informante.

AngioDynamics (ANGO) informó actividad de insiders por su vicepresidente ejecutivo de operaciones y su director financiero. Un Formulario 4 muestra la compra de 890 acciones de acciones comunes el 13/10/2025 a un precio de $11,16 por acción, codificado como “P” para una compra.

Después de la transacción, la persona reportante posee de forma beneficiosa 256.629 acciones, manteniéndolas directamente. El documento indica el cargo como EVP y CFO y confirma que el informe fue presentado por una persona informante.

AngioDynamics (ANGO) 은 EVP 및 CFO의 내부자 활동을 보고했습니다. Form 4는 890주의 보통주를 2025-10-13$11.16의 가격으로 매입했음을 “P”로 코딩해 보여줍니다.

거래 후 보고자 은 256,629주의 주식을 직접 보유하고 있습니다. 신고서에는 역할이 EVP 및 CFO로 표시되며 한 명의 보고자가 서류를 제출했다고 확인합니다.

AngioDynamics (ANGO) a signalé une activité d'initié par son EVP et CFO. Un Formulaire 4 montre l'achat de 890 actions de actions ordinaires le 13/10/2025 à un prix de $11,16 par action, codé « P » pour un achat.

Suite à la transaction, la personne déclarant détient favorablement 256 629 actions, détenues directement. Le dépôt indique le rôle comme EVP et CFO et confirme que le rapport a été déposé par une seule personne déclarant.

AngioDynamics (ANGO) meldete Insider-Tätigkeit seines EVP und CFO. Ein Formular 4 zeigt den Kauf von 890 Aktien der Stammaktien am 13.10.2025 zu einem Preis von $11,16 pro Aktie, codiert als „P“ für einen Kauf.

Nach der Transaktion besitzt die meldende Person 256.629 Aktien, direkt gehalten. Die Einreichung gibt die Rolle als EVP und CFO an und bestätigt, dass der Bericht von einer meldenden Person eingereicht wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Trowbridge Stephen A

(Last) (First) (Middle)
14 PLAZA DRIVE

(Street)
LATHAM NY 12110

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP and CFO
3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/13/2025 P 890 A $11.16 256,629 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Lawrence T. Weiss, as Attorney in Fact 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ANGO's CFO report in this Form 4?

A purchase of 890 shares of common stock on 10/13/2025 at $11.16 per share, transaction code P.

How many ANGO shares does the reporting person now own?

Beneficial ownership is 256,629 shares, held directly after the reported transaction.

Who is the reporting person and their role at ANGO?

An officer, serving as EVP and CFO.

Was this filing made by one person or a group?

It was filed by one reporting person.

What was the transaction code and what does it indicate?

The code was P, indicating a purchase.

Were any derivative securities involved?

No. Table II shows no derivative securities reported.
Angiodynamics

NASDAQ:ANGO

ANGO Rankings

ANGO Latest News

ANGO Latest SEC Filings

ANGO Stock Data

482.86M
38.20M
6.84%
93.83%
7.39%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LATHAM